Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota-brain interactions in colitis

Sci Adv. 2023 May 26;9(21):eadf3887. doi: 10.1126/sciadv.adf3887. Epub 2023 May 26.

Abstract

Developing oral nanomedicines that suppress intestinal inflammation while modulating gut microbiota and brain interactions is essential for effectively treating inflammatory bowel disease. Here, we report an oral polyphenol-armored nanomedicine based on tumor necrosis factor-α (TNF-α)-small interfering RNA and gallic acid-mediated graphene quantum dot (GAGQD)-encapsulated bovine serum albumin nanoparticle, with a chitosan and tannin acid (CHI/TA) multilayer. Referred to "armor," the CHI/TA multilayer resists the harsh environment of the gastrointestinal tract and adheres to inflamed colon sites in a targeted manner. TA provides antioxidative stress and prebiotic activities that modulate the diverse gut microbiota. Moreover, GAGQD protected TNF-α-siRNA delivery. Unexpectedly, the armored nanomedicine suppressed hyperactive immune responses and modulated bacterial gut microbiota homeostasis in a mouse model of acute colitis. Notably, the armored nanomedicine alleviated anxiety- and depression-like behaviors and cognitive impairment in mice with colitis. This armor strategy sheds light on the effect of oral nanomedicines on bacterial gut microbiome-brain interactions.

MeSH terms

  • Animals
  • Bacteria
  • Brain / pathology
  • Colitis* / drug therapy
  • Disease Models, Animal
  • Gastrointestinal Microbiome*
  • Mice
  • Mice, Inbred C57BL
  • Nanomedicine
  • Polyphenols / pharmacology
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Polyphenols
  • Tumor Necrosis Factor-alpha